Stem Cell Study for Patients With Heart Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-09-30

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if stem cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will relieve your chest pain, increase the blood flow, and/or improve the cardiac contractility (function) by regenerating blood vessels in your heart.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stem Cell Study for Patients With Heart Disease

NCT00081913

Chest Pain Myocardial Ischemia Heart Disease +2 more

COMPLETED PHASE1

Stem Cell Study for Patients With Heart Failure

NCT00346177

Myocardial Ischemia Congestive Heart Failure Cardiovascular Disease

WITHDRAWN PHASE2

Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina

NCT05711849

Refractory Angina Pectoris Refractory Angina

RECRUITING PHASE2

Stem Cell Study for Subjects With Congestive Heart Failure

NCT00620048

Myocardial Ischemia Congestive Heart Failure Cardiovascular Disease

TERMINATED PHASE1

Effects of Intracoronary Progenitor Cell Therapy on Coronary Flow Reserve After Acute MI

NCT00711542

Coronary Artery Disease Acute Myocardial Infarction

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic myocardial ischemia (MI) is a progressive disease, which arises as a result of atherosclerosis in coronary arteries. Prognosis of chronic MI is poor, and no effective treatments have been established in patients who are not eligible for the traditional revascularization therapies such as angioplasty and bypass procedures due to the inappropriate anatomy of the coronary arteries or frequent reocclusion following revascularization. Therefore, it is necessary to establish novel revascularization treatment to improve prognosis of the no-option patients. We will study the safety and clinical efficiency of vascular regeneration by means of transplantation of autologous peripheral blood endothelial progenitor cells (CD34 positive cells) in patients with severe chronic coronary artery disease (CAD) who are not eligible for traditional revascularization treatments. The primary endpoint is the severity of myocardial ischemia identified by sestamibi SPECT stress myocardial scintigraphy and the evaluation of adverse effect rates, while the secondary endpoints are evaluation of CCSAS and NYHA classification, regional myocardial blood flow as revealed by PET scan, and various left ventricular function indices.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chest Pain Chronic Myocardial Ischemia Coronary Artery Disease Angina Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autologous peripheral blood CD34 positive cell therapy

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

-Chronic severe CAD patients fulfilling all the following criteria are considered suitable for inclusion in the study.

1. At least 6 months since last episode of myocardial infarction or at least 3 months since initial anginal episode.
2. Patients fulfilling either of the following criteria based on the extent of CAD by coronary angiography and LVEF by echocardiography.

* Patients with single vessel CAD and LVEF \< 50%
* Patients with multivessel CAD
3. Reversible myocardial ischemia as revealed by sestamibi SPECT stress myocardial scintigraphy.
4. Patients for whom angioplasty and bypass are not indicated because of anatomical or procedural reasons or frequent reocclusion/restenosis following traditional revascularization.
5. Age is between 20 and 80 (at time of consent).
6. Exercise tolerance time (ETT) duration ≥ 3 minutes and \< 13 minutes on a modified Bruce protocol on 2 consecutive tests (\> 24 hours but \< 2 weeks apart), with the difference between the 2 exercise times within 25% of their mean (Patients should not be informed of exercise restrictions required for entry into the study).
7. Patients who can give informed consent themselves in writing.

Exclusion Criteria

1. Sustained ventricular tachycardia in a 24-hour ECG.
2. Chronic atrial fibrillation.
3. Less than 6 months since last episode of cerebral infarction.
4. Less than 6 months since last coronary angioplasty or less than 3 months since last bypass surgery.
5. Patients with unstable angina, with a treatment rating of 3 in the Braunwald system (refer to 5.4.), but a severity of III and a clinical rating of B or C.
6. Presence of left ventricular thrombus by echocardiography
7. Patients with a malignant tumor\*.
8. Patients with diabetic proliferating retinopathy\*\* (new Fukuda classification BI to BV).
9. Patients with chronic rheumatoid arthritis.
10. Patients with a history of severe allergic reactions or side effects to G-CSF preparations or apheresis.
11. Patients with hematological disease (leukemia, myeloproliferative disease, or myelodysplastic syndromes).
12. Patients currently suffering from or having a history of interstitial pneumonitis.
13. Patients for whom cranial MRA reveals cerebral aneurysm.
14. Patients for whom abdominal CT or ultrasonography reveals splenomegaly.
15. Patients with cirrhosis of the liver.
16. Patients who cannot discontinue Warfarin.
17. Leukocytes less than 4,000/µL or exceeding 10,000/µL.
18. Platelets less than 100,000/µL.
19. Hemoglobin less than 10 g/dL.
20. AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L.
21. Patients for whom it is impossible to perform both cardiac MRI and left ventriculography (LVG) (see 9.2.4 for cardiac MRI details and 9.2.9 for LVG details).
22. Patients with gate disturbance for reasons other than CAD (such as critical limb ischemia, sciatic neuralgia, or vasculitis), making exercise tolerance evaluation on a treadmill with stress ECG difficult.
23. Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period.
24. Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No